Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 6/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.42 |
| ▸ | IGF1R | P08069 | 5/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13629179 | 0.91 | TNK2 (0.47) | TNK2FGFR4FGFR1FGFR3IGF1R | |
| SCHEMBL13629015 | 0.85 | TNK2 (0.45) | TNK2FGFR4FGFR1FGFR3RAF1 | |
| SCHEMBL8399399 | 0.84 | RAF1 (0.45) | TNK2RAF1SRC | |
| SCHEMBL10241497 | 0.83 | RAF1 (0.47) | TNK2IGF1RRAF1SRC | |
| SCHEMBL8400148 | 0.82 | BTK (0.54) | TNK2IGF1RRAF1SRC | |
| SCHEMBL10240981 | 0.81 | RAF1 (0.59) | TNK2IGF1RRAF1SRC | |
| SCHEMBL10242091 | 0.81 | TNK2 (0.51) | TNK2IGF1RRAF1SRC | |
| SCHEMBL8410126 | 0.80 | TNK2 (0.43) | TNK2RAF1SRC | |
| SCHEMBL8402298 | 0.80 | BTK (0.45) | TNK2FGFR4FGFR1FGFR3RAF1 | |
| SCHEMBL10240965 | 0.80 | TNK2 (0.48) | TNK2IGF1RRAF1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114846-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-02-14 | — | — | US | disclosed |
| US-7923555-B2 | Fused bicyclic mTor inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20100166776-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-7700594-B2 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | MTOR, RICTOR, MAPKAP1 | TNK2 669/4885GAA 2157/4885FGFR4 326/4885 |
| US-20100166776-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | EGFR, ERBB2, RICTOR | TNK2 10/4885GAA 1689/4885FGFR4 30/4885 |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | MTOR, MAPKAP1, RPS6KA1 | TNK2 164/4885GAA 2198/4885FGFR4 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.